IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by RFG Advisory LLC

RFG Advisory LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.9% in the 1st quarter, Holdings Channel reports. The fund owned 1,232 shares of the company’s stock after selling 24 shares during the quarter. RFG Advisory LLC’s holdings in IDEXX Laboratories were worth $665,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IDXX. Norges Bank purchased a new stake in IDEXX Laboratories in the 4th quarter valued at $512,190,000. International Assets Investment Management LLC grew its holdings in shares of IDEXX Laboratories by 51,631.3% in the fourth quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock valued at $304,075,000 after purchasing an additional 546,775 shares during the period. Capital Research Global Investors purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $135,910,000. TD Asset Management Inc increased its position in IDEXX Laboratories by 178.8% during the fourth quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock worth $144,317,000 after purchasing an additional 166,751 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in IDEXX Laboratories during the fourth quarter worth about $78,001,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on IDXX shares. Morgan Stanley decreased their price objective on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Finally, Barclays reduced their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $580.38.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $495.73 on Monday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The company has a market cap of $40.94 billion, a price-to-earnings ratio of 47.99, a price-to-earnings-growth ratio of 4.05 and a beta of 1.33. The stock’s 50-day moving average is $500.80 and its two-hundred day moving average is $528.29. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. Analysts forecast that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

Insider Activity

In related news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.